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Design, Synthesis and Biological 
Evaluation of novel Hedgehog 
Inhibitors for treating Pancreatic 
Cancer
Vinod Kumar1, Amit Kumar Chaudhary1, Yuxiang Dong1, Haizhen A. Zhong2, Goutam 
Mondal1, Feng Lin1, Virender Kumar1 & Ram I. Mahato1
Hedgehog (Hh) pathway is involved in epithelial-mesenchymal transition (EMT) and cancer stem cell 
(CSC) maintenance resulting in tumor progression. GDC-0449, an inhibitor of Hh pathway component 
smoothened (Smo) has shown promise in the treatment of various cancers including pancreatic cancer. 
However, the emergence of resistance during GDC-0449 treatment with numerous side effects limits 
its use. Therefore, here we report the design, synthesis and evaluation of novel GDC-0449 analogs 
using N-[3-(2-pyridinyl) phenyl] benzamide scaffold. Cell-based screening followed by molecular 
simulation revealed 2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-N4,N4-bis(2-pyridinylmethyl)-1,4-
benzenedicarboxamide (MDB5) as most potent analog, binding with an extra interactions in seven-
transmembrane (7-TM) domain of Smo due to an additional 2-pyridylmethyl group than GDC-0449. 
Moreover, MDB5 was more efficient in inhibiting Hh pathway components as measured by Gli-1 and 
Shh at transcriptional and translational levels. Additionally, a significant reduction of ALDH1, CD44 and 
Oct-3/4, key markers of pancreatic CSC was observed when MIA PaCa-2 cells were treated with MDB5 
compared to GDC-0449. In a pancreatic tumor mouse model, MDB5 containing nanoparticles treated 
group showed significant inhibition of tumor growth without loss in body weight. These evidence 
highlight the enhanced Hh pathway inhibition and anticancer properties of MDB5 leaving a platform for 
mono and/or combination therapy.
Hedgehog (Hh) signaling regulates cell growth, differentiation and plays a major role in homeostasis of various 
organs and tissues by affecting stem cells1–3. Aberrant activation of Hh pathway associates itself with a variety of 
human tumors resulting in tumorigenesis, malignancy and metastasis; which in normal cells is less active2, 4, 5. The 
first association of Hh signaling in cancer was established after Gorlin’s syndrome resulting from an autosomal loss 
of Patched (Ptch)6. Follow-up studies revealed activation of this pathway in basal cell carcinoma (BCC), medul-
loblastoma (MB), leukemia, breast, esophagus, gastric, pancreatic, prostate and small-cell lung cancers7–13. Hh 
signaling is a key regulator of physiological processes which plays a key role in cancer stem cell (CSC) biology14. 
Profound attention has been given to explore the role of CSC in the initiation and progression of solid malignan-
cies. These cells are responsible for tumor onset, self-renewal, maintenance and metastasis due to their ability 
to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth15, 16. Conventional therapy 
merely kill most differentiated tumor cells except CSCs, which have intrinsic detoxifying mechanisms and can 
easily escape these therapies. CSCs and epithelial-mesenchymal transition (EMT) type cells have been proposed 
to play critical roles in chemoresistance and metastasis as demonstrated in several malignancies.
The development of small molecule targeting cancer-associated signaling pathways has been viewed as a 
promising approach for the treatment of solid tumors. Anticancer agents targeting several modules of the Hh 
pathway have been described. While most Hh pathway antagonists target a seven-transmembrane (7-TM) 
domain of Smoothened (Smo), components upstream and downstream of Smo are also being investigated as 
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potential pharmaceutical targets17. The first example that a small molecule could effectively inhibit Hh pathway 
came from a natural product cyclopamine which binds Smo resulting in Hh pathway inactivation18.
GDC-0449 is the first FDA– approved Hh pathway inhibitor for the treatment of metastatic or locally 
advanced BCC19. Soon after GDC-0449, sonidegib was approved by the FDA as the second clinically prescribed 
Smo antagonist20. Dense desmoplasia in pancreatic ductal adenocarcinoma (PDAC) consists of primarily pan-
creatic stellate cell (PSC), fibroblasts and ECM proteins. It is driven by Hh signaling and limits the delivery of 
chemotherapy. GDC-0449 has shown the potential in reducing desmoplasia by targeting Smo. Despite the signif-
icant accomplishment in the development of Hh pathway inhibitors, the clinical use of GDC-0449 and sonidegib 
is severely restricted due to numerous side effects including constipation, diarrhea, decreased appetite, hair loss, 
muscle spasms, and tiredness19, 21. To overcome these obstacles, several Hh pathway inhibitors that target Smo 
have been developed. For instance, Castanedo et al., developed more potent second generation benzamide for 
inhibiting Hh pathway using N-[3-(2-pyridinyl) phenyl] benzamide scaffold common to the clinical lead com-
pound GDC-044922. Unfortunately, in addition to above restrictions, several challenges in the discovery and 
development process for small molecules targeting Hh pathway have been noted. For example, development of 
resistance to these drugs has become a major hurdle for their continued advancement23–26. Although treatment of 
MB patients with GDC-0449 demonstrated initial positive results, relapse was observed when a point mutation 
occurs in Smo rendering the patient insensitive to subsequent GDC-0449 treatment23. Moreover, regrowth of at 
least single BCC patient has been observed, when 21% of patients received continuous GDC-0449 treatment27. 
Also, aberrant expression of zinc finger transcription factor Gli, Phosphoinositide 3-kinase signaling pathway 
and low solubility of GDC-0449 limits its use28, 29. These bottlenecks of Hh pathway inhibitors have prompted an 
extensive search for novel inhibitors to function via mechanisms that will retain activity in the presence of path-
way signaling resistant to current therapy.
Pancreatic cancer (PC) is one of the most aggressive and difficult cancers to treat. Limited success has been 
achieved in the therapeutic management of patients with this disease despite numerous research efforts. Hh path-
way inhibitors are relatively new class of therapeutic agents that act by targeting Hh pathway protein components 
like Ptch, Smo, Gli and Sonic hedgehog (Shh). Together, they serve as exciting new prospects for PC treatment, 
both alone or as an adjuvant to the more traditional anticancer drugs. Therefore, development of better Hh path-
way inhibitors with the understanding of the correlation between CSCs and EMT will help in cancer treatment. In 
this study, we have reported the use of structure-activity relationship (SAR) to design and synthesize novel GDC-
0449 analogs with improved Hh pathway inhibition and anticancer properties. After screening of all the ana-
logs, 2-chloro-N1-[4-chloro-3-(2-pyridinyl) phenyl]-N4,N4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide 
(MDB5) was found to be the best as evident from in vitro and in vivo studies.
Results and Discussion
Designing and Screening of GDC-0449 Analogs. PC is a leading cause of cancer-related mortality with 
a dismal 5–7% five-year survival rate. The current FDA-approved chemotherapeutic agent for PC is gemcitabine, 
which provides only symptomatic improvement in a lesser proportion of patients. New combination therapy 
FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan and oxaliplatin) showed improvement compared to 
gemcitabine alone; however, there was a significant rate of grade 3/4 toxicity in PC patients30.
Hh signaling plays a critical role in the formation of desmoplastic stroma; thus, promoting tumor growth and 
serve as a barrier to chemotherapy. This pathway is initiated when a family of Hh ligand (Desert, Indian or Shh) 
interacts with a cell surface transmembrane receptor Ptch (Ptch-1 and Ptch-2). This interaction relieves repres-
sion of Smo receptor and subsequently activate the downstream signaling. Activated Hh cascade permits nuclear 
localization of Gli family of transcription factors (Gli-1 and, Gli-2) that regulate the expression of genes associated 
with proliferation, angiogenesis, stemness and metastasis2, 4, 5. On the other hand, the tumor suppressor SuFu 
(suppressor of fused) negatively regulates Hh pathway by binding and sequestering Gli transcription factors in 
the cytoplasm31–33. Aberrant activation of Hh pathway has been shown to associate itself with a variety of human 
tumors including PDAC. Our earlier work on combining GDC-0449 with gemcitabine has shown synergistic 
downregulation of Hh pathway components inducing apoptosis34. Similar results were also seen in a panel of 
human PC cell lines including pancreatic CSC with GDC-044935. Although Hh inhibitor GDC-0449 overcomes 
desmoplastic reaction by blocking oncogenic Smo involved in Hh signaling, its clinical use is restricted due to 
side effects and development of chemoresistance. Therefore, in this study, we considered GDC-0449 as a promis-
ing lead to further explore SAR around chlorobenzene (moiety 2) by using N-[3-(2-pyridinyl)phenyl]benzamide 
scaffold following synthetic scheme shown in Fig. 1. Since ortho-chloro group in moiety 2 is critical for GDC-
0449 solubility, we focused our attention on moiety 322, 36.
Keeping moieties 1 and 2, we replaced methylsulfonyl group (moiety 3) with N-(4-chloro-3-(pyridin-2-yl)
phenyl)amido group in GDC-0449 to generate MDB1 (Fig. 2a). The introduction of an additional N-(4-chloro-
3-(pyridin-2-yl) phenyl)amido group in GDC-0449 did not show any enhanced cytotoxic effect in MIA PaCa-2 
cells than GDC-0449 (Fig. 2b). This indicated that replacing moiety 3 with N-(4-chloro-3-(pyridin-2-yl) phenyl)
amido group disrupted ligand-receptor interaction, thus leading to an undesirable activity (Table 1). A recent 
study shows that generation of 2-pyridyl biphenyl amides was potent in inhibiting Hh pathway as measured by 
Gli-1 transcript22. Therefore, we next replaced moiety 3 of GDC-0449 with N-(pyridin-2-ylmethyl)amido group 
to generate 2-pyridyl biphenyl amide 14f (abbreviated as MDB2) (Fig. 2a). The improved cell cytotoxicity profile 
of MDB2 in MIA PaCa-2 cells clearly suggest N-(pyridin-2-ylmethyl)amido group to be an important moiety for 
enhanced cytotoxic effect (Fig. 2b). To further exploit the benefit brought by N-(pyridin-2-ylmethyl)amido group, 
we replaced moiety 1 with N-(pyridin-2-ylmethyl)amido group in MDB2 to generate MDB3 (Fig. 2a). Although 
MDB3 contains two N-(pyridin-2-ylmethyl)amido groups at para positions of moiety 2, it did not exhibit bet-
ter cytotoxic activity than GDC-0449 (Fig. 2b). In contrast, the presence of single N-(4-chloro-3-(pyridin-2-yl) 
phenyl)amido and single N-(pyridin-2-ylmethyl)amido groups around moiety 2 in MDB2 has better activity 
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compared to GDC-0449. These results suggest that moiety 1 is not only necessary for solubility but also for bio-
activity of GDC-0449. Therefore, we next increased the number of 2-pyridylmethyl group by attaching them to 
the same nitrogen atom in the amide-bond of MDB2, generating MDB5 (Fig. 2a). The substitution of moiety 3 
of GDC-0449 with N,N-bis(pyridin-2-ylmethyl)amido group significantly improved cytotoxic activity in MIA 
PaCa-2 and PANC-1 cells (Fig. 2b and c). In the spirit of finding more potent analogs, we next replaced moieties 2 
and 3 of GDC-0449 to generate MDB4 and MDB6 (Fig. 2a). In MDB4, we replaced –Cl with –CF3 in moiety 2 and 
methylsulfonyl in moiety 3 with methanesulfonamido group, whereas in MDB6, we replaced the chlorobenzene 
with methylpyridine in moiety 2 and moiety 3 with 4-acetyl-1-peperainyl group, respectively. Unfortunately, we 
did not observe any improved cytotoxic activity from MDB4 and MDB6 than GDC-0449 (Fig. 2b).
Regulation of Hedgehog Signaling Through Smo Binding. To test our hypothesis that an addi-
tional 2-pyridylmethyl group in MDB5 is necessary for the enhancement of Hh pathway inhibition and cell 
cytotoxicity, we performed molecular docking studies with human Smo containing 7-TM and extracellular 
cysteine-rich ligand-binding domains37. Followed by Smo crystal structures (PDB ID: 5L7I, 4QIM, 4QIN, 4O9R 
and 4N4W) alignment and docking of reference compounds, we observed GDC-0449, Anta XV (2-(6-(4-(4-ben
zylphthalazin-1-yl)piperazin-1-yl)pyridin-3-yl)propan-2-ol), SAG1.5 (3-chloro-4,7-difluoro-N-[trans-4-(meth-
ylamino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]methyl]-1-benzothiophene-2-carboxamide) and cyclopamine 
to bind in the similar pocket closer to the upper opening of 7-TM domain. However, SANT-1 (N-[(1E)-
(3,5-dimethyl-1-phenyl-1-hpyrazol-4-yl)methylidene]-4-(phenylmethyl)-1-piperazinamine) was found to be a 
deep-pocket binder (Fig. 3a)38. Further, the docking of GDC-0449 and its analogs to Smo yielded MDB5 as the 
strongest binder with the docking score of −12.84 kcal/mol, the lowest among all (Fig. 3b) (Table 1). Inspection 
of the binding interactions between stronger binders (MDB2 and MDB5) versus GDC-0449 showed some shared 
and distinct interactions for each compound. Where all of them shared similar hydrogen-bonding with Asp384 
and Arg400 to amide-bond, Tyr394 shared to pyridine nitrogen atom (Fig. 3b–d). These common interactions 
suggest the importance of pyridine ring (ortho to the chlorine atom) and amide-bond (para to the chlorine atom) 
in moiety 1. The importance of moiety 1 was validated by our current study, which shows that, replacement of 
moiety 1 with a pyridine ring significantly reduced the activity of MDB3. In addition to the common interactions, 
MDB2 and MDB5 possess different interactions due to their distinct structural features. For instance, the two 
Figure 1. Schematic representation of GDC-0449 analogs synthesis. 2-chloro-N1,N4-bis[4-chloro-3-(2-
pyridinyl)phenyl]-1,4-benzenedicarboxamide (MDB1), 2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-
N4-(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDB2), 2-chloro-N1,N4-bis(2-pyridinylmethyl)-
1,4-benzenedicarboxamide (MDB3), N-[4-chloro-3-(2-pyridinyl)phenyl]-4-[(methylsulfonyl)amino]-
2-(trifluoromethyl)benzamide (MDB4), 2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-N4,N4-bis(2-
pyridinylmethyl)-1,4-benzenedicarboxamide (MDB5) and 6-(4-acetyl-1-piperazinyl)-N-[4-chloro-3-(2-
pyridinyl)phenyl]-2-methyl-3-pyridinecarboxamide (MDB6) were synthesized using N-[3-(2-pyridinyl) 
phenyl]benzamide scaffold of GDC-9449.
www.nature.com/scientificreports/
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pyridinylmethyl groups on MDB5 allows further interactions with Asp382, Tyr397 and Phe484 (Fig. 3b). For 
MDB2, the mono pyridinylmethyl group forms interactions with Asp382 and Phe484, thus making MDB2 a 
weaker binder than MDB5 due to the missing interactions with Tyr397. However, the additional interactions with 
Smo still make MDB2, a stronger binder than GDC-0449 (Fig. 3b,c and d). Therefore, the pyridinylmethyl groups 
(mono or di-substituent) would need to be kept in future structural optimization. Caution needs to be taken that 
the space composed of Asp382, Tyr397 and Phe484 is limited allowing certain structural modifications. Structural 
modifications that lead to large groups would weaken the binding. For instance, the additional moiety 1 of MDB1, 
however, made it too bulky for 7-TM domain of Smo, thus caused steric repulsion with Phe484 leading to much 
weaker activity. Pharmacodynamically, MDB1 was predicted to have a similar binding score as MDB3. However, 
the much larger hydrophobicity of MDB1 (logP 7) makes it more difficult to absorb and becomes more disrup-
tive to Smo binding. Both pharmacodynamics and pharmacokinetic properties of MDB1 contributed to weaker 
docking scores and observed weaker activities (Table 1).
Human PC cells (AsPC-1, PANC-1, and MIA-PaCa-2) and pancreatic CSC express differential level of Hh 
pathway components (Ptch, Smo, Gli and Shh) and mesenchymal markers35, 39. Under physiological condition, 
Hh pathway inhibitors target these components, disturbing the downstream signaling. Our earlier study has 
shown that the combination of GDC-0449 and gemcitabine has distinct effects on MIA PaCa-2 cells compared 
to others34. Similar effects were seen when GDC-0449 was combined with miR-let7b on MIA PaCa-2 cells, as 
Figure 2. (a) Structure-activity relationship (SAR) to design GDC-0449 analogs. (b,c) Cell cytotoxicity assay of 
MIA PaCa-2 and PANC-1 cells treated with free drugs. Percentage of viable cells were estimated by MTT assay. 
Data is shown as the mean ± S.D. of three separate experiments (Student t-test; *p < 0.05; **p < 0.001; n = 3).
DRUGS IC50 (μM) Wild-type D473H W281C
GDC-0449 97.36 −9.41 −7.21 −9.10
MDB1 >100 −8.68 −9.08 −9.61
MDB2 79.73 −11.61 −9.88 −10.98
MDB3 >100 −8.90 −8.54 −9.01
MDB4 89.33 −9.91 −7.73 −9.32
MDB5 55.57 −12.84 −10.76 −11.52
MDB6 >100 −10.13 −8.33 −9.69
Table 1. IC50 (μM) in MIA PaCa-2 cells and docking scores (kcal/mol) of respective drugs in wild-type Smo, 
D473H and W281C mutants of Smo.
www.nature.com/scientificreports/
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the aberrant expression of miRNAs is critical for cancer initiation and progression28, 40. Since MIA PaCa-2 and 
PANC-1 cells express profound level of Hh pathway components35, we observed a significant reduction of Gli-1 
and Shh proteins in these cells after MDB5 treatment (Fig. 4a and c)22. Similarly, a decrease in Gli-1, Gli-2, Ptch 
and Shh transcripts were also evident in MDB5 treated MIA PaCa-2 cells compared to GDC-0449 (Fig. 4b). Since 
transcription factors Gli is known to play a regulatory role in cell cycle and apoptosis; our observations suggest 
MDB5 act on Hh pathway with much more Smo binding capacity than GDC-0449.
As GDC-0449 is Smo antagonist; we further sought to validate our molecular simulation in Smo knockdown 
cells using Smo specific siRNA. As shown in Fig. 4e, GDC-0449 and MDB5 were unable to show cytotoxic effect 
when MIA PaCa-2 cells were transfected with ON-TARGETplus Smo specific siRNA before drug treatment. 
However, a similar cytotoxic effect was observed when the cells were transfected with non-targeting siRNA before 
drug treatment (Figs 2b and 4d,e). These observations clearly suggest that MDB5 acts via Smo and share a com-
mon pathway like its parent compound GDC-0449, thus did not show any cytotoxic effect after inhibition of Smo 
expression like GDC-0449.
Although GDC-0449 overcomes impenetrable desmoplastic stroma, its clinical use is limited mainly due to 
the development of mutations in Smo leading to chemoresistance. Smo mutant D473H has shown to rendered 
resistance to GDC-044941 by reducing its binding to Smo with 100-fold compared to the wild-type42. Similarly, 
mutant W281C decreases binding affinity of GDC-0449 to Smo by 40-fold as measured by Kd43. Therefore, to 
evaluate the binding of our analogs to Smo mutants, we generated Smo mutants computationally by mutating 
D473 into His (D473H) and W281 into Cys (W281C), followed by docking of MDB1–6 and GDC-0449. The 
binding scores of GDC-0449 to D473H and W281C dropped from −9.41 kcal/mol in wild-type to −7.21 and 
−9.10 kcal/mol respectively, which is in good agreement with the observation that D473H and W281C signifi-
cantly reduced GDC-0449 binding. In contrast, the binding scores of MDB5 to D473H and W281C increases to 
−10.76 and −11.52 kcal/mol respectively, compared to GDC-0449 showing its tighter binding affinity than GDC-
0449 (Table 1). These evidence suggested MDB5 may still be sensitive to D473H and W281C mutants due to the 
lower docking scores compared to GDC-0449.
Regulation of Apoptosis and Cell Cycle Arrest. Apoptosis plays a major role in maintaining the home-
ostasis of normal cells. Cellular shrinkage and DNA fragmentation at the molecular level are characteristics 
acquired during apoptosis44. Therefore, we performed flow cytometric analysis using MIA PaCa-2 cells, where 
the total apoptotic cells populations significantly increased from 7.75% in GDC-0449 to 45.1% in MDB5, whereas 
Figure 3. Molecular docking of GDC-0449 analogs in human Smo. (a) Binding pocket of Smo as defined 
by superposition of five crystal structures of human Smo (PDB ID: 5L7I, 4QIM, 4QIN, 4O9R and 4N4W). 
Structures and ligands were colored coded as noted. Smo/ligand interactions for MDB5 (b), MDB2 (c) and 
GDC-0449 (d). The hydrogen-bond interactions are depicted as orange dotted lines.
www.nature.com/scientificreports/
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10.85% and 5.7% of apoptotic cells were seen in MDB2 and control treated samples, respectively (Fig. 5a and b). 
Since Bax pro-apoptotic protein accelerates the cell death in response to apoptotic stimuli, we next measured the 
level of Bax as an indicator of apoptosis. In Fig. 4a and c, we observed increased Bax expression in MIA PaCa-2 
and PANC-1 cells treated with MDB5 compared to GDC-0449. In contrast, the anti-apoptotic protein Bcl-2 was 
significantly downregulated in cells induced by MDB5 compared to GDC-0449. As Bcl-2 is overexpressed in 
various cancers and contribute to treatment resistance by inhibiting chemotherapy-induced apoptosis45, 46, our 
observations provide a reasonable mechanistic explanation of the observed cell death induction.
Based on our molecular simulation and Smo knockdown study, it is clear that MDB5 exerts antiproliferative 
effect by targeting and destabilizing Smo. Therefore, we next performed cell cycle analysis by flow cytometry to 
Figure 4. Effect of MDB5 on Hh pathway and target genes. (a) Western blot analysis for Gli-1, Shh, Bcl-2, Bax 
and GAPDH of MIA PaCa-2 cells treated with GDC-0449 and MDB5. (b) Real-time RT-PCR analysis of Gli-1, 
Gli-2, Ptch-1 and Shh of MIA PaCa-2 cells treated with GDC-0449 and MDB5. (c) Western blot analysis for Gli-
1, Shh, Bcl-2, Bax and GAPDH of PANC-1 cells treated with GDC-0449 and MDB5. (d) Transfection of labeled 
oligonucleotide using Lipofectamine® RNAiMAX in MIA PaCa-2 cells. (e) Cell cytotoxicity assay of GDC-0449 
and MDB5 in Smo knockdown MIA PaCa-2 cells. Percentage of viable MIA PaCa-2 cells was estimated by MTT 
assay. Data is shown as mean ± SD of three separate experiments (Student t-test; *p < 0.05; n = 3). Cropped 
Western blots are shown. Full-length Western blots are included in the Supplementary Information (Fig. S14).
Figure 5. (a) Induction of apoptosis by MDB5 in MIA PaCa-2 cells. (b) Graphical representation of total 
percentage of apoptosis induced by GDC-0449 and MDB5 (Student t-test; *p < 0.05 vs. control). (c) Analysis of 
cell cycle arrest in MIA PaCa-2 cells. The graphical representation of percentage of cells in G0/G1, G2/M and 
S-phase of the cell cycle (Student t-test; *p < 0.05, n = 3).
www.nature.com/scientificreports/
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evaluate the effect of MDB5 on cell cycle arrest. We observed a significant increment in S-phase from 16.15% in 
GDC-0449 to 21.25% and 29.27% in MDB2 and MDB5 treated MIA PaCa-2 cells, respectively. This result con-
firmed that the anticancer effect of MDB5 is through the arrest of cell cycle in S-phase and subsequent activation 
of intrinsic apoptotic cellular machinery. In contrast, a significant reduction of cells in G1-phase was evident in 
MDB2 and MDB5 treated cells, respectively (Fig. 5c).
Role of GDC-0449 Analogs on Pancreatic CSC, Cell Migration and Tumorigenicity. There is a 
growing attention that CSCs are often related to metastasis, chemoresistance and EMT phenotype47–49. The resist-
ance to chemotherapy of CSCs prevents the eradication of cancer and presents the looming threat of recurrence. 
The growing evidence suggest the existence of CSCs in PC overexpressing aldehyde dehydrogenases (ALDH), 
CD44 and Oct-3/4 including others50–57. Studies show that ALDH-high cells comprise more sub-population of 
cells in human PC that are tumorigenic and capable of producing tumors at very low numbers58. Recently, Singh 
et al. show that GDC-0499 inhibits pancreatic CSC cell viability and induces apoptosis through caspase-3 activa-
tion and poly (ADP-ribose) polymerase (PARP) cleavage35. Therefore, we examined the expression of ALDH1, 
CD44 and Oct-3/4 to further confirm the effect of MDB5 on pancreatic CSC. As shown in Fig. 6a, a significant 
reduction in ALDH1, CD44 and Oct-3/4 was observed in MIA PaCa-2 cells indicating the ability of MDB5 to 
kill pancreatic CSC effectively than GDC-0449. Moreover, a significant reduction of Bcl-2 by MDB5 in MIA 
PaCa-2 and PANC-1 cells compared to GDC-0449 provides an additional reasonable explanation of MDB5 effect 
on pancreatic CSC (Fig. 4a and c). Likewise, a significant decrease of Gli-1, Gli-2, Ptch-1 and Shh transcripts as 
supported by Singh et al.35 studies provide an additional explanation that MDB5 is more efficient in inhibiting 
pancreatic CSC compared to GDC-0449 (Fig. 4b).
During EMT, the cells lose their epithelial features including loss of sheet-like architecture and polarity result-
ing in migration, invasion and increased tumorigenic potential59–61. A recent study shows that the activated Hh 
pathway promoting tumorigenicity and stemness via EMT, attenuate cell motility, invasiveness, and clonogenic 
Figure 6. (a) Western blot analysis of pancreatic CSC markers in MIA PaCa-2 cells after GDC-0449 and MDB5 
treatment. (b) Effect of GDC-0449 and MDB5 on MIA PaCa-2 cells motility. (c) Effect of GDC-0449 and 
MDB5 on colony formation of MIA PaCa-2 cells. (d) Effect of GDC-0449 and MDB5 on 3D spheroid of MIA 
PaCa-2 cells. (e) Cell cytotoxicity assay of MIA PaCa-2 cells treated with GDC-0449 and MDB5 containing 
nanoparticles. Percentage of viable MIA PaCa-2 cells was estimated by MTT assay. Data are shown as the 
mean ± S.D. of three separate experiments (Student t-test; *p < 0.05; **p < 0.001; n = 3). Cropped Western blots 
are shown. Full-length Western blots are included in the Supplementary Information (Fig. S14).
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 1665  | DOI:10.1038/s41598-017-01942-7
potential of bladder and non-small cell lung cancers after GDC-0449 treatment62, 63. As EMT is relevant to the 
acquisition and maintenance of stem cell-like characteristics and is sufficient to endow differentiated normal and 
cancer cells with stem cell properties, we next checked the effect of MDB5 on cell migration and tumorigenic 
potential of MIA PaCa-2 cells. Supporting our other results, we observed a significant decrease in the number 
of migratory cells in MDB5 treated highly invasive and metastatic PC cells compared to GDC-0449 and MDB2 
(Fig. 6b). Additionally, MDB5 also reduces the tumorigenic potential of MIA PaCa-2 cells significantly compared 
to GDC-0449 and MDB2, respectively (Fig. 6c). These evidence supported MDB5 to be more potent in reducing 
pancreatic CSC, invasive and tumorigenic potential of PC affecting EMT phenotypes.
Effects of MDB5 on 3D Spheroids and In Vivo Tumor Regression. Recently, increasing numbers of 
cell culture experiments with 3D spheroids presented better correlating results in vivo than traditional 2D culture 
systems. It became apparent that 3D cultures are more resistant to chemo-radiotherapy than their 2D counter-
parts. Compared to 2D culture models, 3D spheroids can accurately mimic features of solid tumors, such as their 
spatial architecture, physiological responses, secretion of soluble mediators, production of extracellular matrix, 
gene expression patterns and drug resistance mechanisms. These unique characteristics highlight the potential 
of 3D spheroids and offer a simple and highly reproducible model for in vitro drug screening64, 65. Most drugs 
that pass preclinical tests successfully, fail miserably in the patient due to traditional 2D culture for drug screen-
ing. Therefore, we developed 3D spheroids of MIA PaCa-2 cells, and as evident from our 2D culture MTT assay 
(Fig. 2b), we observed a significant reduction in spheroid size in MDB5 treated group compared to GDC-0449 
(Fig. 6d). This result further supports MDB5 as more potent analog than GDC-0449.
A suitable formulation of drugs is an essential step in drug development. However, most drugs are usu-
ally developed for intravenous use, despite drawbacks like thrombosis and extravasation, and risk of 
intravenous-catheter-related infection66. Additionally, solubility is a specific demand for intravenous adminis-
tration of drugs, even for poor water-soluble new generation of chemotherapeutic agents. Classical solubilizing 
approaches including the use of Tween 80 and/or cremophor EL significantly increased the solubility of hydro-
phobic drugs and protect them from premature degradation within the systemic circulation. However, these 
solubilizing agents are usually associated with liver and kidney toxicity, hemolysis, acute hypersensitivity reaction 
and peripheral neuropathies67. Since GDC-0449 analogs are hydrophobic in nature, the use of solubilizing agents 
and surfactants for in vivo delivery may cause organ and system toxicity. In our earlier study, bicalutamide-loaded 
PEG-b-P(CB-co-LA) micelles68 and LY293-loaded mPEG-b-P(CB-co-LA) nanoparticles69 showed exceptional 
efficacy in inhibiting human prostate cancer and melanoma, respectively. Also, mPEG-b-P(CB-co-LA) nano-
particles provided an excellent platform to co-deliver different poorly soluble drugs like GDC-0449 and PPAR-γ 
agonist, rosiglitazone, respectively to treat liver fibrosis70. As nanoparticles improve the pharmacokinetic profiles, 
increases solubility and drug loading with reduced toxicity, in the present study, we used mPEG-b-P(CB-co-LA) 
nanoparticles for in vivo delivery of MDB5. To continue this endeavor, we formulated biodegradable polymeric 
nanoparticles to evaluate the efficacy of GDC-0449 and MDB5 in subcutaneous pancreatic tumor bearing NSG 
mice generated using MIA PaCa-2 cells. Nanoparticles were prepared using mPEG-b-p(CB-b-LA) copolymer 
with the mean particle size of 113.6 ± 5 nm and 132.6 ± 2 nm for GDC-0449 and MDB5, respectively (Fig. S13). 
Following drug loading of 5% (Fig. S13), MIAPaCa-2 cells treated with nanoparticles containing MDB5 showed 
similar inhibition of cell viability as of free drugs (Fig. 2b) in dose-dependent manner (Fig. 6e). Following in vitro 
analysis, the mice treated with nanoparticles containing GDC-0449 and MDB5 showed a significant reduction in 
tumor growth compared to control (392.22 ± 52.43 mm3). There was much more reduction in tumor growth in 
the mice treated with nanoparticles carrying MDB5 (103.56 ± 16.25 mm3) compared to mice treated with nano-
particles carrying GDC-0449 (237.25 ± 42.76 mm3). Also, no significant changes in body weight of the animals 
were observed during the study indicating tolerance to the doses of GDC-0449 and MDB5 (Fig. 7a–d).
Further, to elucidate the superior anticancer effect of MDB5, we performed immunohistochemical analysis of 
proliferation (Ki-67), apoptosis (cleaved caspase-3) and EMT (E-cadherin) markers. As shown in Fig. 7e, nano-
particles containing MDB5-treated mice displayed a lesser level of Ki-67 but a higher level of cleaved caspase-3 
and E-cadherin compared to nanoparticles containing GDC-0449 and control treated tumors, respectively 
(Fig. 7e). Additionally, histological staining of mice treated with PBS (control) showed loss of cellular architecture 
with hypercellularity, whereas mice treated with nanoparticles containing MDB5 showed a significant pyknosis, 
compared to nanoparticles containing GDC-0449 treated tumors (Fig. 7f). Also, histological staining of major 
organs (kidney, spleen, liver, lung and heart) did not show any pathological changes after treatment in all the 
groups (Fig. 8). These promising results obtained from treated groups of mice further confirmed MDB5 to be 
effective in the inhibition Hh pathway and most potent anticancer agent with negligible systemic toxicity.
Additionally, at tested dose of 20 and 40 mg/kg of MDB5, we did not observe any significant changes in bio-
chemical parameters of such as alanine aminotransferase (ALT) and total bilirubin (TBIL) in treated animals 
compared to the control group confirming negligible hepatic injury (Table S1).
Conclusions
Smo is a major component of Hh signaling which play a major role in the development and metastasis of PC. 
In the spirit of finding more potent GDC-0449 analogs, in this study, we designed and synthesized six analogs 
(MDB1-6). Among these analogs, MDB5 showed better Hh pathway inhibition and anticancer activities than 
GDC-0449. Significant upregulation of Bax and downregulation of Bcl-2, Gli-1, Shh, ALDH1, CD44 and Oct-
3/4 proteins by MDB5 confirms its better Hh pathway and pancreatic CSC inhibition properties compared to 
GDC-0449. Our molecular docking suggested that MDB5 binds with extra interactions in 7-TM domain of 
Smo due to the presence of an additional 2-pyridylmethyl group and thus became a stronger binder than GDC-
0449. Additionally, our studies agreed with the experimental observation that mutants D473H and W281C led 
to decreased binding affinity toward GDC-0449 and that our best compound MDB5 might still be sensitive to 
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mutants D473H and W281C, which would be possible due extra binding interactions observed MDB5. Compared 
to GDC-0449, MDB5 significantly inhibited the tumor growth without any systemic toxicity. These evidence 
highlight the enhanced Hh pathway inhibition and anticancer properties of MDB5.
Hh signaling is not only limited to cancer but also to other diseases. In liver fibrosis, secretion of growth 
factors and Hh ligands by hepatic parenchyma upon repeated insults results in transdifferentiation of quiescent 
hepatic stellate cells (HSCs) into active myofibroblasts which secrete excessive amounts of extracellular matrix 
(ECM) proteins. Therefore, Hh pathway inhibitors can play a major role in treating liver fibrosis by inhibiting 
several pro-fibrotic genes29, 70, 71. In conclusion, further exploration of GDC-0449 analog can leave a platform for 
developing more potent Hh inhibitors for treating diseases related to Hh signaling.
Figure 7. In vivo efficacy of nanoparticles carrying GDC-0449 and MDB5 in tumor bearing mice. (a) 
Animals body weight during treatment. (b) Representative tumor size of various treatment groups. (c) Tumor 
volume. (d) Tumor weight. Data are expressed as the mean ± S.E. (n = 5) (Student t-test; *p < 0.05, n = 5). (e) 
Immunohistochemical analysis of tumor samples by Ki-67, Cleaved-caspase 3 and E-cadherin staining. Scale 
bar, 100 μm. (f) H&E staining of tumor samples. Scale bar, 100 μm.
Figure 8. Immunohistochemical analysis of major organs (kidney, spleen, liver, lung and heart) by H&E 
staining. Scale bar, 100 µM.
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Methods
Chemicals and Reagents. GDC-0449 (Vismodegib) was purchased from LC Laboratories (Woburn, 
MA). TaqMan reverse transcription reagent kit was purchased from Life Technologies (Grand Island, NY). 
Radioimmunoprecipitation assay (RIPA) buffer and SYBR green-1 were purchased from Roche (Indianapolis, 
IN). All other reagents including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
2-chloroterephthalic acid (C8H5ClO4), thionyl chloride (SOCl2), dimethylformamide (DMF), dichlorometh-
ane (CH2Cl2), 4-chloro-3-(pyridin-2-yl)benzenamine (C11H9ClN2), triethanolamine (TEA), dimethylaceta-
mide (DMA), acetonitrile (ACN), 3-chloro-4-(methoxycarbonyl) benzoic acid (C9H7ClO4), 2-(aminomethyl)
pyridine (C6H8N2), hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 
ethyl acetate (EtOAc), magnesium sulfate (MgSO4), potassium hydroxide (KOH), methanol (CH3OH), dimethyl 
ether (DME), N,N-diisopropylethylamine (DIPEA), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]
pyridinium 3-oxid hexafluorophosphate) (HATU), bis(2-pyridylmethyl)amine (C12H13N3), 6-chloro-2-meth-
ylpyridine-3-carboxylic acid (C7H6ClNO2), 1-acetylpiperazine (C6H12N2O), 4-(methanesulfonylamino)-2-(tri-
fluoromethyl)benzoic acid were purchased from Sigma-Aldrich (St. Louis, MO).
Synthesis of GDC-0449 analogs. Figures S1–S12 shows the synthetic scheme and structural characteriza-
tion of MDB1, MDB2, MDB3, MDB4 and MDB6.
2-chloro-N1,N4-bis[4-chloro-3-(2-pyridinyl)phenyl]-1,4-benzenedicarboxamide (MDB1). MDB1 was syn-
thesized by heating a mixture of C8H5ClO4 (506 mg, 2.52 mmol), SOCl2 (2 mL) and DMF (a drop) in CH2Cl2 
(5 mL) at 50 °C for 17 h. The reaction was cooled to room temperature and concentrated. The residue was diluted 
with CH2Cl2 (10 mL) and concentrated to dryness. To the residue was added a solution of C11H9ClN2 (1.03 g, 
5.04 mmol) and TEA (1.0 g, 10 mmol) in DMA (10 mL). The mixture was stirred at room temperature for 24 h 
and then quenched with water (50 mL). The resulting precipitate was collected by filtration, rinsed with ACN 
(20 mL), and dried to give the diamide MDB1 (1.07 g, 74%) as a white solid. Mp 130–132 °C. 1H NMR (500 MHz, 
DMSO-d6) 7.43–7.47 (m, 2H), 7.58–7.61 (m, 2H), 7.69–7.73 (m, 2H), 7.77–7.82 (m, 2H), 7.91–7.97 (m, 3H), 
8.03–8.09 (m, 3H), 8.19 (s, 1H), 8.70–8.73 (m, 2H), 10.65 (s, 1H), 10.88 (s, 1H); 13C NMR (125.7 MHz, DMSO-d6) 
121.13, 121.79, 122.60, 123.16, 123.46, 124.69, 125.80, 126.91, 128.88, 129.29, 130.34, 130.39, 130.53, 136.60, 
137.05, 137.98, 138.11, 139.16, 139.31, 139.39, 149.65, 149.67, 156.02, 163.69, 164.66.
2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-N4-(2-pyridinylmethyl)-1,4-benzenedicarboxamide 
(MDB2). MDB2 was synthesized in two steps. In first step, to a mixture of C9H7ClO4 (1.07 g, 5 mmol), C6H8N2 
(810 mg, 7.5 mmol), HOBt (675 mg, 5 mmol), and TEA (1.01 g, 10 mmol) in DMA (20 mL) was added EDCI 
(1.44 g, 7.5 mmol). The mixture was stirred at room temperature for 17 h and then quenched with water (100 mL). 
The mixture was extracted with EtOAc (3 × 50 mL). The organic layers were washed with water (50 mL) and 
brine (50 mL), dried over MgSO4, filtered and concentrated. In second step, a mixture of the crude amide and 
KOH (561 mg, 10 mmol) in CH3OH (50 mL) was heated at 50 °C for 17 h and cooled to room temperature. After 
removal of the solvent, the residue was purified by crystallization from CH2Cl2 (20 mL) to give the desired potas-
sium salt MDB2 as a white solid (1.80 g). Step 3. A mixture of the potassium salt (0.90 g), SOCl2 (1 mL) and 
DMF (a drop) in DME (5 mL) was heated at 60 °C for 17 h. The reaction was cooled to room temperature and 
concentrated. The residue was diluted with DME (5 mL) and concentrated to dryness. To the residue was added 
a solution of C11H9ClN2 (410 mg, 2 mmol) and TEA (404 mg, 4 mmol) in DMA (10 mL). The mixture was stirred 
at room temperature for 24 h and then quenched with brine (50 mL). After the solvent was decanted, the residue 
was purified by crystallization from water to afford the desired diamide MDB2 (513 mg, 43%) as a white solid. 
Mp 94–96 °C. 1H NMR (500 MHz, DMSO-d6) 4.61 (d, J = 5.5 Hz, 2H), 7.25–7.31 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 
7.42–7.47 (m, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.71–7.81 (m, 3H), 7.91–7.95 (m, 1H), 7.99 
(dd, J = 8.0, 1.0 Hz, 1H), 8.04 (d, J = 2.5 Hz, 1H), 8.10 (s, 1H), 8.53 (d, J = 4.0 Hz, 1H), 8.72 (d, J = 4.5 Hz, 1H), 9.37 
(t, J = 5.5 Hz, 1H), 10.85 (s, 1H); 13C NMR (125.7 MHz, DMSO-d6) 45.02, 121.12, 121.22, 122.35, 122.59, 123.15, 
124.69, 125.79, 126.41, 128.57, 129.26, 130.34, 130.51, 136.59, 136.85, 136.93, 137.99, 138.95, 139.37, 149.08, 
149.66, 156.02, 158.51, 164.60, 164.73.
2-chloro-N1,N4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDB3). MDB3 was synthesized as follows. 
To a mixture of C8H5ClO4 (401 mg, 2 mmol) and C6H8N2 (649 mg, 6 mmol), HOBt (270 mg, 2 mmol), and TEA 
(606 mg, 6 mmol) in DMA (10 mL) was added EDCI (1.15 g, 6 mmol). The mixture was stirred at room temper-
ature for 24 h and then quenched with water (100 mL). The mixture was extracted with EtOAc (3 × 50 mL). The 
combined organic layers were washed with water (50 mL) and brine (50 mL), dried over MgSO4, filtered, and 
concentrated. The crude product was purified by crystallization from ACN to give the desired product (253 mg, 
33%) as a white solid. Mp 143–145 °C. 1H NMR (500 MHz, DMSO-d6) 4.57 (d, J = 6.0 Hz, 2H), 4.59 (d, J = 6.0 Hz, 
2H), 7.25–7.31 (m, 2H), 7.34 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.77 (td, J = 8.0, 
1.5 Hz, 1H), 7.81 (td, J = 8.0, 1.5 Hz, 1H), 7.94 (dd, J = 8.0, 1.0 Hz, 1H), 8.05 (s, 1H), 8.49–8.55 (m, 2H), 9.17 (t, 
J = 6.0 Hz, 1H), 9.33 (t, J = 6.0 Hz, 1H); 13C NMR (125.7 MHz, DMSO-d6) 44.75, 45.00, 121.09, 121.22, 122.34, 
122.38, 126.30, 128.54, 129.23, 130.28, 136.49, 136.92, 136.97, 139.20, 149.06, 149.07, 158.31, 158.54, 164.68, 
166.26.
N-[4-chloro-3-(2-pyridinyl)phenyl]-4-[(methylsulfonyl)amino]-2-(trifluoromethyl)benzamide (MDB4). MDB4 
was synthesized as follows. To a mixture of 4-(methanesulfonylamino)-2-(trifluoromethyl)benzoic acid (312 mg, 
1.1 mmol) and C11H9ClN2 (205 mg, 1 mmol), and DIPEA (129 mg, 1 mmol) in ACN (10 mL) was added HATU 
(570 mg, 1.5 mmol). The mixture was stirred at room temperature for 17 h and then evaporated to dryness. The 
crude product was purified by crystallization from EtOH/water (1:2) to give the desired product (384 mg, 82%) 
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as a white solid. Mp 181–183 °C. 1H NMR (500 MHz, DMSO-d6) 3.13 (s, 3H), 7.42–7.51 (m, 1H), 7.51–7.59 (m, 
3H), 7.67–7.75 (m, 3H), 7.93 (td, J = 8.0, 2.0 Hz, 1H), 8.00 (d, J = 2.5 Hz, 1H), 8.71 (d, J = 5.0 Hz, 1H), 10.40 (s, 
1H), 10.75 (s, 1H).
2-chloro-N1-[4-chloro-3-(2-pyridinyl) phenyl]-N4,N4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide 
(MDB5). MDB5 was synthesized in two steps. In the first step, to a mixture of C9H7ClO4 (540 mg, 2.5 mmol), 
C12H13N3 (740 mg, 3.7 mmol), and TEA (505 mg, 5 mmol) in ACN (25 mL) was added HATU (1.43 g, 3.75 mmol). 
The mixture was stirred at room temperature for 17 h and then evaporated to dryness. The residue was diluted 
with CH2Cl2 (50 mL) and extracted with brine (3 × 50 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated. In the second step, a mixture of the crude amide and KOH (291 mg, 5.2 mmol) in CH3OH (25 mL) 
was heated at 50 °C for 17 h and cooled to room temperature. After removal of the solvent, the residue was puri-
fied by crystallization from ACN (50 mL) to give the desired potassium salt as a white solid. In step three, to a 
mixture of the potassium salt and 4-chloro-3-(pyridin-2-yl) benzenamine (197 mg, 0.96 mmol) in DMA (5 mL) 
HATU (547 mg, 1.4 mmol) was added. The mixture was stirred at room temperature for 17 h and then quenched 
with brine (50 mL). The resulting precipitate was collected by filtration and dried. The crude product was purified 
by chromatography (silica gel, EtOAc/ACN = 50:50) to afford the desired diamide (149 mg, 10%) as a white solid. 
Mp 89–91 °C. 1H NMR (500 MHz, DMSO-d6) 4.63 (s, 2H), 4.70 (s, 2H), 7.27–7.39 (m, 3H), 7.42–7.46 (m, 2H), 
7.56 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.64–7.69 (m, 2H), 7.72–7.82 (m, 4H), 7.90–7.94 (m, 1H), 8.00 
(d, J = 2.0 Hz, 1H), 8.53 (d, J = 3.5 Hz, 1H), 8.61 (d, J = 3.0 Hz, 1H), 8.70 (d, J = 3.5 Hz, 1H), 10.77 (s, 1H); 13C 
NMR (125.7 MHz, DMSO-d6) 50.17, 54.02, 121.03, 121.91, 122.38, 122.48, 122.56, 123.04, 123.15, 124.67, 125.72, 
127.96, 129.25, 130.18, 130.48, 136.58, 137.10, 137.25, 137.36, 138.00, 139.25, 139.35, 149.21, 149.65, 149.72, 
155.86, 156.02, 156.71, 164.69, 169.52.
6-(4-acetyl-1-piperazinyl)-N-[4-chloro-3-(2-pyridinyl)phenyl]-2-methyl-3-pyridinecarboxamide (MDB6). MDB6 
was synthesized in two steps. In first step, to a mixture of C7H6ClNO2 (189 mg, 1.1 mmol), C11H9ClN2 (205 mg, 
1 mmol), and DIPEA (129 mg, 1 mmol) in ACN (10 mL) was added HATU (570 mg, 1.5 mmol). The mixture was 
stirred at room temperature for 17 h and then quenched with water (50 mL). The resulting precipitate was col-
lected by filtration and dried to give the desired amide (167 mg, 47%) as a white solid. In second step, a mixture 
of the intermediate (167 mg, 0.47 mmol) and C6H12N2O (179 mg, 1.4 mmol) in DMA (5 mL) was heated at 140 °C 
for 72 h. The reaction was cooled to room temperature and quenched with water (50 mL). The resulting precipitate 
was collected by filtration, rinsed with ACN (20 mL), and dried to give the desired product (169 mg, 80%) as a 
white solid. Mp 222–224 °C. 1H NMR (500 MHz, DMSO-d6) 2.05 (s, 3H), 2.48 (s, 3H), 3.51–3.65 (m, 8H), 6.75 (d, 
J = 9.0 Hz, 1H), 7.41–7.47 (m, 1H), 7.52 (d, J = 9.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.81 
(dd, J = 8.5, 2.0 Hz, 1H), 7.92 (t, J = 8.0 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 8.70 (d, J = 4.5 Hz, 1H), 10.34 (s, 1H).
In vitro cell cytotoxicity assay. 5 × 103 MIA PaCa-2 and PANC-1 cells per well were seeded in 96-well 
plate and incubated in 5% CO2 at 37 °C in a 95% humidified atmosphere. After 24 h, the cells were treated with 
concentration gradients of GDC-0449 analogs (MDB1–6) (0–100 µM in DMSO) and cell viability was assessed 
by MTT (0.5 mg/mL) assay after 72 h34. 0.25% of DMSO was used as a control in all the experiments hereafter. 
Additionally, GDC-0449 and MDB5 loaded nanoparticles were also used for MTT assay.
To validate MDB5 to share same molecular pathway with GDC-0449, MIA PaCa-2 cells were seeded into 
6-well plate at a density of 2 × 105 cells/well in DMEM medium. At 70–80% cells confluency, ON-TARGETplus 
siRNA for Smo and ON-TARGETplus non-targeting pool as control siRNA (50 pmol/well) (Dharmacon, Inc.) 
was transfected in MIA PaCa-2 cells using Lipofectamine® RNAiMAX according to manufacturer’s instructions 
(Thermo Scientific, Rockford, IL). Post 24 h of transfection, cells were treated with 50 µM of drugs and cell viabil-
ity was assessed by MTT. Labeled oligonucleotide (50 pmol/well) was compled with Lipofectamine® RNAiMAX 
and transfected according to manufacturer’s instructions and visualized under a fluorescent microscope.
Molecular docking. The docking study of GDC-0449 analogs was carried out using Glide docking approach 
(Protein Preparation Wizard)72. The crystal structures of human Smo were retrieved through Protein Data Bank 
(PDB ID: 5L7I, 4QIM, 4QIN, 4O9R and 4N4W). These structures were superimposed using the Molecular 
Operating Environment program (MOE) (Chemical Computing Group Inc. Montreal, Canada) to identify the 
binding sites for subsequent docking studies. Proteins were prepared using the Protein Preparation Wizard at 
Maestro to flip the side-chain structures of residues Gln and Asn to maximize hydrogen-bond interactions. The 
grid file for 5L7I was generated using the Glide Grid Generation protocol with the bound ligand as the centroid. 
Ligand structures were constructed, minimized using the Maestro program, and subsequently docked to the 
model protein as defined in the grid file. During the docking process, the scaling factor for receptor van der Waals 
for the nonpolar-atoms was set to 0.8 to allow for a certain degree of receptor flexibility and the extra precision 
method was used. All other parameters were used as defaults. The binding affinity of the Smo/ligand complexes 
was expressed as docking scores, where the more negative docking score suggests more favorable ligand binding. 
The figures of protein/ligand interactions were generated with the Pymol program (Delano Scientific LLC, San 
Carlos, CA), and hydrogen atoms are hidden for clarity purposes.
Molecular docking in Smo mutants was carried by mutating the residues to respective mutant using MOE’s 
mutate function, following by energy minimization. After minimization, protein mutants were prepared using 
Schrodinger Maestro’s protein preparation module, and with side chain minimized using minimizers in Maestro. 
After that, grid files were generated using Glide dock protein, and then all ligands were docked to the grid files, 
which represent the binding pocket. After docking, ligands were evaluated based on their docking scores.
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Apoptosis and cell cycle analysis. 3 × 105 MIA PaCa-2 cells per well were grown in 6 wells plate for 
24 h. After 24 h, the cells were treated with 50 µM of drugs. After 72 h post treatment, both live and dead cells 
were collected, washed twice with cold PBS and the pellets were suspended in 500 µL binding buffer containing 
5 µL of annexin-V FITC and 1 µL of propidium iodide (100 µg/mL) (Alexa Fluor® 488 annexin V Apoptosis Kit, 
Invitrogen). The mixture was incubated for 15 min in the dark at room temperature and analyzed by flow cytom-
etry. For cell cycle analysis, after harvesting total cells, the pellets were suspended in 1 mL of cold 70% ethanol 
and incubated overnight at 4 °C for fixation. The next day, cells were washed twice with cold PBS and suspended 
in 500 µl FxCycle PI/RNase staining solution (Molecular Probes) and analyzed by FACS Calibur flow cytometer 
after incubated at 37 °C for 30 min in the dark.
Colony formation and cell migration assay. The clonogenic assay was carried out by treating 1 × 103 
MIA PaCa-2 cells with 50 µM of drugs for 7 days. The cells forming the colonies were determined under a fluo-
rescent microscope after staining with crystal violet. For migration study, 5 × 104 MIA PaCa-2 cells were trans-
ferred into the upper chambers of the Transwell plates (8.0 μm transparent PET Membrane) in 2.5 ml DMEM 
supplemented with 1% FBS. The lower chamber was filled with 3 ml DMEM supplemented with 10% FBS. After 
24 h of incubation at 37 °C under 5% CO2, cells were treated with drugs and further incubated for another 72 h at 
the same condition. The migrated cells were determined after staining with crystal violet and observed under a 
fluorescent microscope.
Quantitative real-time RT-PCR and Western blot analysis. For quantitative real-time RT-PCR 
analysis, after 72 h of treatment with 50 µM of drugs, MIA PaCa-2 cells was lysed and the total RNA was 
extracted using RNeasy Mini Kit (QIAGEN, MD) followed by reverse transcription into cDNA55. Real-time 
RT-PCR was then performed to amplify cDNA using SYBR Green dye universal master mix on a Light 
Cycler 480 (Roche, Indianapolis) using the primers for Gli-1-F: 5′-CCAACTCCA CAGGCATACAGGAT-3′, 
R: 5′-CACAGATTCAGGCTCACGCTTC-3′; Gli-2-F: 5′-AAGTCACTCAAGGATTCCTGCTCA-3′, 
R: 5′-GTTTTCCAGGATGGAGCCACTT-3′ ; Shh-F: 5′-CCGGCTTCGACTGGGTGTACTA-3′ , R: 
5′-CGCCACCGAGTTCTCTGCTTT-3′ ;  Smo-F: 5′-GCTACTTCCTCATCCGAGGAGTCA-3′ ,  R: 
5 ′-GGCGCAGCATGGTCTCGTT-3 ′ ;  and GAPDH-F: 5 ′-ACCACAGTCCATGCCATCAC-3 ′ ,  R: 
5′-TCCACCACCCTGTTGCTGTA-3′ for forty cycles. For Western blot analysis, protein was isolated from 
MIA PaCa-2 and PANC-1 cells after treatment with 50 µM of drugs and concentration were determined using 
Micro BCATM Protein assay kit (Thermo Scientific, Rockford, IL). Equal amounts of protein were separated in 
4–15% mini PROTEAN polyacrylamide gel followed by transferring to polyvinylidenefluoride (PVDF) (Life 
Technologies, Carlsbad, CA) membranes by iBlot gel transfer system. Membranes were blocked for 1 h at room 
temperature with blocking buffer containing 5% non-fat dry milk and 0.05% Tween-20 in 1X PBST. Membranes 
were incubated overnight with primary antibodies for Gli-1 (sc-20687), Shh (sc-9024), Bcl-2 (sc-492), Bax 
(sc-70406), ALDH1/2 (sc-166362), Oct-3/4 (sc-5279), GAPDH (sc-365062) (Santa Cruz Biotechnology, Inc.) 
and CD44 (3578) (Cell Signaling Technology, Inc.). Following washing with PBST, the membranes were incu-
bated with their corresponding horseradish peroxidase-conjugated secondary antibodies (sc-2055, sc-2054 and 
sc-2056) (Santa Cruz Biotechnology, Inc.). Target proteins were detected by ImmunoCruz Western blotting 
luminol reagent kit (Santa Cruz Biotechnology, Inc.). To ascertain comparative expression and equal loading of 
the protein samples, the membrane stained earlier was stripped and re-probed with GAPDH and other target 
antibodies.
3D spheroid culture. For 3D spheroid generation, 3 × 103 cells in 40 μl DMEM medium per well were 
seeded onto Perfecta3D® 96-Well Hanging Drop Plates (3D Biomatrix, Inc., Ann Arbor MI) in triplicate and 
incubated at 37 °C, 5% CO2 over the course of time. After the formation of 3D spheroid on day 3, the spheroids 
were treated with 50 µM of drugs on 4th day and images were taken under a fluorescent microscope. Following 
treatment, images were taken at 3rd, 7th and 9th days to check the cytotoxic effect of drugs on 3D spheroid.
Polymer synthesis and preparation nanoparticles.  Methoxy-polyethylene-g lyco
l-b-poly(carbonate-co-lactide) [mPEG-b-p(CB-b-LA)] copolymer was synthesized as described previously70. 
Nanoparticles carrying drugs were prepared using mPEG-b-p(CB-b-LA) by the emulsion/solvent evaporation 
technique69. The particle size distribution of nanoparticles was determined by dynamic light scattering using a 
Zeta SizerTM (Malvern 3800-ZLS, Boston, MA). Drug loading and encapsulation efficiency were determined by 
HPLC (Waters Corporation, Milford, MA). Briefly, GDC-0449, and MDB5 loaded nanoparticles with 0.5 mg 
theoretical drug loading were dissolved in 500 µL of DCM for drug extraction using a bath sonicator for 15 min 
at 37 °C. The solution containing DCM was collected, evaporated and the residues were dissolved in ACN. Drug 
content was determined by HPLC using a reverse phase C-18 Inertsil ODS column (150 mm × 4.6 mm, 5 μm) (GL 
Sciences Inc., Torrance, CA). Mobile phase composition was ACN and water (70:30) at a flow rate of 0.65 mL/
min. Detection wavelength of 228 nm and 261.5 nm were used for GDC-0449 and MDB5, respectively.
In vivo evaluation. All in vivo animal experiments were carried out as per the NIH animal use guidelines 
and protocol approved (#14-060-09-FC) by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Nebraska Medical Center (UNMC), Omaha, NE. Tumor flank was established in 8–10-week-old 
male NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ (NSG) mice by subcutaneous injection of 3 × 106 MIA PaCa-2 cells 
suspended in a total 50 µL of 1:1 PBS and Matrigel (BD Biosciences, San Diego, CA). When the tumor volume 
reached 100–120 mm3, animals were randomly divided into three groups (n = 5), i.e., control (PBS), nanoparti-
cles containing GDC-0449 and nanoparticles containing MDB5. Formulations were administered intravenously 
thrice a week for 3 weeks at an equivalent drugs dose of 20 mg/kg. Tumor size was measured at regular intervals 
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using a digital vernier caliper and body weight of the animals was recorded thrice a week. At the end of study, 
tumors were excised, weighed, and images were taken.
Immunohistochemical staining and in vivo toxicity analysis. Mice tumor sections were stained with 
H&E, Ki-67, cleaved-caspase 3 and E-cadherin to determine toxicity, cell proliferation, apoptosis and EMT phe-
notype after drugs treatment. The toxic effects of MDB5 on major organs (kidney, spleen, liver, lung and heart) 
were determined by H&E staining. Positively stained (brown color) was selected for relative intensity.
For evaluation of short-term toxicity, when the volume of subcutaneous tumor reached 200 mm3, animals 
were randomly divided into two groups (n = 5), i.e., control (PBS) and MDB5 emulsion formulated by 65% 
dextrose solution and 35% of emulsifying agents (50% propylen glycol, 30% cremophore EL and 20% ethanol). 
Formulations were administered intraperitoneally thrice a week for 4 weeks at an equivalent drugs dose of 20 and 
40 mg/kg. At the end of study, blood was collected in lithium heparin tubes (LH/1.3) via cardiac puncture and 
blood chemistry markers (hepatic) for each group were quantified following our earlier protocol73, 74.
Statistical analysis. Student’s unpaired t-test was used to compare the mean values of individual groups. A 
p value < 0.05 was considered as statistically significant.
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